Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY9.62 CNY
Change Today -0.31 / -3.12%
Volume 20.2M
600285 On Other Exchanges
Symbol
Exchange
Shanghai
As of 3:05 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

henan lingrui pharmaceutic-a (600285) Snapshot

Open
CNY9.30
Previous Close
CNY9.93
Day High
CNY10.84
Day Low
CNY9.30
52 Week High
06/12/15 - CNY17.91
52 Week Low
09/17/14 - CNY7.98
Market Cap
5.2B
Average Volume 10 Days
19.1M
EPS TTM
CNY0.22
Shares Outstanding
535.5M
EX-Date
06/11/15
P/E TM
43.5x
Dividend
CNY0.06
Dividend Yield
0.62%
Current Stock Chart for HENAN LINGRUI PHARMACEUTIC-A (600285)

Related News

No related news articles were found.

henan lingrui pharmaceutic-a (600285) Related Businessweek News

No Related Businessweek News Found

henan lingrui pharmaceutic-a (600285) Details

Henan Lingrui Pharmaceutical Co., Ltd. is engaged in the production and sale of pharmaceutical products in China. The company offers pharmaceutical products in 10 dosage forms comprising adhesive plasters, tablets, capsules, granules, tinctures, etc. covering approximately 100 product varieties, such as Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, Shenqi Hypoglycemic capsules, and others. It provides patch, oral medicine, and other products. The company was founded in 1992 and is based in Xinyang, China.

henan lingrui pharmaceutic-a (600285) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

henan lingrui pharmaceutic-a (600285) Key Developments

Henan Lingrui Pharmaceutical Co., Ltd. Announces Earnings Results for the First Six Months of Fiscal 2015

Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the first six months of fiscal 2015. For the six months, the company announced basic earnings per share of CNY 0.153 and weighted average return on net assets of 4.72%.

Henan Lingrui Pharmaceutical Co., Ltd., Board Meeting, Aug 26, 2015

Henan Lingrui Pharmaceutical Co., Ltd., Board Meeting, Aug 26, 2015. Agenda: To discuss and approve the proposal of 'semi-annual report of 2015 and its abstract; and to approve the proposal of implementation of project of pasting products with annual output of 10 billion pieces.

Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2015 Results on Aug 28, 2015

Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report first half, 2015 results on Aug 28, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600285:CH CNY9.62 CNY -0.31

600285 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600285.
View Industry Companies
 

Industry Analysis

600285

Industry Average

Valuation 600285 Industry Range
Price/Earnings 44.1x
Price/Sales 5.5x
Price/Book 2.8x
Price/Cash Flow 43.3x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HENAN LINGRUI PHARMACEUTIC-A, please visit www.lingrui.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.